These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 8756097)
21. [Interferon alpha--the drug of choice for patients with chronic myeloid leukemia]. Klamová H; Vítek A; Michalová K; Brezinová J; Moravcová J; Jelínek J; Cermák J Cas Lek Cesk; 1998 Sep; 137(18):552-6. PubMed ID: 9818464 [TBL] [Abstract][Full Text] [Related]
22. Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Steegmann JL; Moreno G; Aláez C; Osorio S; Granda A; de la Cámara R; Arranz E; Reino FG; Salvanés FR; Fernández-Rañada JM; Muñoz C Haematologica; 2003 Jul; 88(7):762-8. PubMed ID: 12857554 [TBL] [Abstract][Full Text] [Related]
23. A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia. Meloni G; Russo D; Baccarani M; Testoni N; Martinelli G; Fanin R; Zuffa E; Rosti G; Alimena G; Saglio G; Mandelli F; Tura S Haematologica; 1999 Aug; 84(8):707-15. PubMed ID: 10457406 [TBL] [Abstract][Full Text] [Related]
24. [The retreatment with natural leukocyte interferon alfa-n3 of chronic hepatitis C patients: the intolerant and nonresponsive results to prior treatment with recombinant alfa interferon]. Cagnoni C; Pancotti D; Carrara G Ann Ital Med Int; 1999; 14(3):159-65. PubMed ID: 10566181 [TBL] [Abstract][Full Text] [Related]
25. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha. Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029 [TBL] [Abstract][Full Text] [Related]
26. Donor leukocyte infusion for relapsed ANLL after allogeneic BMT and the use of interferon alpha to induce graft-versus-leukemia effect. Gürman G; Arslan O; Koç H; Akan H Bone Marrow Transplant; 1996 Oct; 18(4):825-6. PubMed ID: 8899208 [No Abstract] [Full Text] [Related]
27. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Zeuzem S; Schmidt JM; Lee JH; von Wagner M; Teuber G; Roth WK Hepatology; 1998 Jul; 28(1):245-52. PubMed ID: 9657119 [TBL] [Abstract][Full Text] [Related]
28. [The influence of interferon alpha neutralizing antibodies on the therapeutic effectiveness in patients with chronic viral hepatitis]. Tong F; Tang Y; Bai J Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Dec; 13(4):345-7. PubMed ID: 12759973 [TBL] [Abstract][Full Text] [Related]
29. Clinical experience of antibodies to interferon-alpha during treatment of chronic myeloid leukemia. Russo D; Candoni A; Grattoni R J Interferon Cytokine Res; 1997 Jul; 17 Suppl 1():S47-9. PubMed ID: 9241616 [TBL] [Abstract][Full Text] [Related]
30. Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation. Steegmann JL; Casado LF; Tomás JF; Sanz-Rodríguez C; Granados E; de la Cámara R; Alegre A; Vázquez L; Ferro MT; Figuera A; Arranz R; Fernández-Rañada JM Bone Marrow Transplant; 1999 Mar; 23(5):483-8. PubMed ID: 10100563 [TBL] [Abstract][Full Text] [Related]
31. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Kantarjian HM; O'Brien S; Cortes JE; Shan J; Giles FJ; Rios MB; Faderl SH; Wierda WG; Ferrajoli A; Verstovsek S; Keating MJ; Freireich EJ; Talpaz M Cancer; 2003 Feb; 97(4):1033-41. PubMed ID: 12569603 [TBL] [Abstract][Full Text] [Related]
32. [Occurrence of autoimmune complications in patients with chronic myelocytic leukemia during treatment with interferon alfa]. Tóthová E; Stecová N; Kafková A; Fricová M; Svorcová E Vnitr Lek; 2002 May; 48(5):380-3. PubMed ID: 12061203 [TBL] [Abstract][Full Text] [Related]
33. [Results of treatment in patients with hairy cell leukemia with splenectomy, alpha-interferon and deoxycoformycin]. Gotić M; Rolović Z; Radosević N; Draguljac N; Jovanović V; Bogdanović A; Bosković D Srp Arh Celok Lek; 2000; 128(7-8):262-70. PubMed ID: 11089434 [TBL] [Abstract][Full Text] [Related]
34. Interferon alpha in the treatment of chronic myelogenous leukemia. Robak T Arch Immunol Ther Exp (Warsz); 1998; 46(6):347-53. PubMed ID: 9883313 [TBL] [Abstract][Full Text] [Related]
35. Successful application of highly purified natural interferon alpha (multiferon) in a chronic hepatitis C patient resistant to preceding treatment approaches. Musch E; Malek M; von Eick H; Chrissafidou A Hepatogastroenterology; 2004; 51(59):1476-9. PubMed ID: 15362781 [TBL] [Abstract][Full Text] [Related]
36. [Busulfan versus busulfan-interferon as maintenance therapy in chronic myeloid leukemia]. López Hernández MA; Flores-Chapa JD; Trueba Christy E; Borbolla Escoboza JR; Carrillo Rosales T Rev Invest Clin; 1996; 48(4):281-7. PubMed ID: 8966391 [TBL] [Abstract][Full Text] [Related]
38. Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy. von Wussow P; Jakschies D; Freund M; Deicher H J Interferon Res; 1989 Sep; 9 Suppl 1():S25-31. PubMed ID: 2809276 [TBL] [Abstract][Full Text] [Related]
39. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group. Prümmer O Cancer; 1993 Mar; 71(5):1828-34. PubMed ID: 8448744 [TBL] [Abstract][Full Text] [Related]
40. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors. Oberg K; Alm GV J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]